Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cardiff Oncology (CRDF) Depreciation & Amortization (CF) (2016 - 2025)

Historic Depreciation & Amortization (CF) for Cardiff Oncology (CRDF) over the last 15 years, with Q3 2025 value amounting to $89000.0.

  • Cardiff Oncology's Depreciation & Amortization (CF) fell 1188.12% to $89000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $372000.0, marking a year-over-year decrease of 948.91%. This contributed to the annual value of $404000.0 for FY2024, which is 150.75% up from last year.
  • According to the latest figures from Q3 2025, Cardiff Oncology's Depreciation & Amortization (CF) is $89000.0, which was down 1188.12% from $94000.0 recorded in Q2 2025.
  • In the past 5 years, Cardiff Oncology's Depreciation & Amortization (CF) ranged from a high of $119000.0 in Q1 2021 and a low of $31000.0 during Q1 2022
  • Over the past 5 years, Cardiff Oncology's median Depreciation & Amortization (CF) value was $98000.0 (recorded in 2023), while the average stood at $92894.7.
  • Its Depreciation & Amortization (CF) has fluctuated over the past 5 years, first plummeted by 7394.96% in 2022, then soared by 19032.26% in 2023.
  • Quarter analysis of 5 years shows Cardiff Oncology's Depreciation & Amortization (CF) stood at $113000.0 in 2021, then fell by 23.89% to $86000.0 in 2022, then rose by 19.77% to $103000.0 in 2023, then decreased by 6.8% to $96000.0 in 2024, then dropped by 7.29% to $89000.0 in 2025.
  • Its last three reported values are $89000.0 in Q3 2025, $94000.0 for Q2 2025, and $93000.0 during Q1 2025.